Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Haematologica|April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsMichael J Hochman, Amy S Ruppert, Ying Huang, et al.
Journal of Cardiothoracic Surgery|June 25, 2024
Methadone in combination with magnesium, ketamine, lidocaine, and dexmedetomidine improves postoperative outcomes after coronary artery bypass grafting: an observational multicentre studyLaurence Weinberg, Samuel Johnston, Luke Fletcher, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022Peter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Blood|February 1, 2023
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromesAmer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, et al.
Nature Medicine|October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master TrialAmy Burd, Ross L Levine, Amy S Ruppert, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.
Blood Neoplasia|April 20, 2026
Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemiaUma Borate, Cristina E Tognon, Yazan F Madanat, et al.
Acta Haematologica|March 5, 2025
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia VeraJohn Mascarenhas, Prithviraj Bose, Christopher Hillis, et al.
Blood Advances|October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AMLSheng F Cai, Ying Huang, Jennie R Lance, et al.
Cancer|April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialVu H Duong, Amy S Ruppert, Alice S Mims, et al.
Pageof 8